Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11900248.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.
Medical subject headings
- Anti-Inflammatory Agents, Non-Steroidal
- Colorectal Neoplasms
- Cyclooxygenase Inhibitors
- Isoenzymes